HER2 Support Group Forums - View Single Post - Further Development of INCB7839 as a New Oral Treatment for Breast Cancer

StephN · 12-16-2007, 03:53 PM

This is one drug I want to keep my eye on. The data was a very small study, but more studies are in the works.
From the article:

Data presented at the San Antonio Breast Cancer Symposium demonstrate that INCB7839:
-- has shown promising clinical activity in heavily pretreated, refractory cancer patients
-- has the potential to provide single-agent efficacy as well as improved clinical outcomes when used in combination with other EGFR targeted therapies, including those that target EGFR or HER2
-- has been generally well-tolerated in both preclinical studies and clinical trials
INCB7839 is also currently in Phase II development. The first of two Phase II trials has been initiated and is designed to determine the effectiveness of INCB7839 when used in combination with Herceptin(R). This trial design is based, in part, on the potent synergy demonstrated preclinically with this combination. A second Phase II trial is planned and expected to begin in 2008 that will evaluate INCB7839 as monotherapy.

12-16-2007, 03:53 PM	#2
StephN Senior Member Join Date: Nov 2004 Location: Misty woods of WA State Posts: 4,128	Wow - complete HER pathway blockage!?! This is one drug I want to keep my eye on. The data was a very small study, but more studies are in the works. From the article: Data presented at the San Antonio Breast Cancer Symposium demonstrate that INCB7839: -- has shown promising clinical activity in heavily pretreated, refractory cancer patients -- has the potential to provide single-agent efficacy as well as improved clinical outcomes when used in combination with other EGFR targeted therapies, including those that target EGFR or HER2 -- has been generally well-tolerated in both preclinical studies and clinical trials INCB7839 is also currently in Phase II development. The first of two Phase II trials has been initiated and is designed to determine the effectiveness of INCB7839 when used in combination with Herceptin(R). This trial design is based, in part, on the potent synergy demonstrated preclinically with this combination. A second Phase II trial is planned and expected to begin in 2008 that will evaluate INCB7839 as monotherapy. __________________ "When I hear music, I fear no danger. I am invulnerable. I see no foe. I am related to the earliest times, and to the latest." H.D. Thoreau Live in the moment. MY STORY SO FAR ~~~~ Found suspicious lump 9/2000 Lumpectomy, then node dissection and port placement Stage IIB, 8 pos nodes of 18, Grade 3, ER & PR - Adriamycin 12 weekly, taxotere 4 rounds 36 rads - very little burning 3 mos after rads liver full of tumors, Stage IV Jan 2002, one spot on sternum Weekly Taxol, Navelbine, Herceptin for 27 rounds to NED! 2003 & 2004 no active disease - 3 weekly Herceptin + Zometa Jan 2005 two mets to brain - Gamma Knife on Jan 18 All clear until treated cerebellum spot showing activity on Jan 2006 brain MRI & brain PET Brain surgery on Feb 9, 2006 - no cancer, 100% radiation necrosis - tumor was still dying Continue as NED while on Herceptin & quarterly Zometa Fall-2006 - off Zometa - watching one small brain spot (scar?) 2007 - spot/scar in brain stable - finished anticoagulation therapy for clot along my port-a-catheter - 3 angioplasties to unblock vena cava 2008 - Brain and body still NED! Port removed and scans in Dec. Dec 2008 - stop Herceptin - Vaccine Trial at U of W begun in Oct. of 2011 STILL NED everywhere in Feb 2014 - on wing & prayer 7/14 - Started twice yearly Zometa for my bones Jan. 2015 checkup still shows NED 2015 Neuropathy in feet - otherwise all OK - still NED. Same news for 2016 and all of 2017. Nov of 2017 - had small skin cancer removed from my face. Will have Zometa end of Jan. 2018.